MARKET

FPRX

FPRX

Five Prime
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.230
+0.030
+0.94%
Closed 16:00 11/19 EST
OPEN
3.200
PREV CLOSE
3.200
HIGH
3.370
LOW
3.180
VOLUME
334.30K
TURNOVER
--
52 WEEK HIGH
13.97
52 WEEK LOW
3.180
MARKET CAP
117.55M
P/E (TTM)
-0.7783
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of FPRX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

FPRX News

  • The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
  • Benzinga.22h ago
  • Our Take On Five Prime Therapeutics
  • Seeking Alpha - Article.1d ago
  • Edited Transcript of FPRX earnings conference call or presentation 6-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.11/12 14:22
  • Daily Insider Ratings Round Up 11/7/19
  • Seeking Alpha - Article.11/11 19:28

More

Industry

Biotechnology & Medical Research
+2.16%
Pharmaceuticals & Medical Research
+0.78%

Hot Stocks

Name
Price
%Change

About FPRX

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.
More

Webull offers Five Prime Therapeutics Inc (FPRX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.